Anthony D Booth

Summary

Country: UK

Publications

  1. ncbi Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation
    A D Booth
    Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Circulation 109:1718-23. 2004
  2. ncbi Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
    Anthony D Booth
    Department of Medicine, Addenbrookes s Hospital, Cambs, UK
    Am J Kidney Dis 41:776-84. 2003
  3. ncbi Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis
    Anthony Booth
    Department of Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Am Soc Nephrol 15:717-21. 2004
  4. ncbi Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom
    J Am Coll Cardiol 50:852-8. 2007
  5. ncbi Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction
    Sharon M L Wallace
    Clinical Pharmacology, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Hypertension 50:228-33. 2007
  6. ncbi Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge, UK
    Int J Cardiol 129:399-405. 2008
  7. ncbi Immunotherapy for autoimmune and inflammatory renal diseases
    Anthony D Booth
    Department of Renal Medicine (Box 118, Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 2QQ, UK
    Expert Opin Biol Ther 3:487-500. 2003
  8. ncbi Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge CB2 2QQ, United Kingdom
    Circulation 114:1185-92. 2006
  9. ncbi Renal vasculitis--an update in 2004
    Anthony D Booth
    Nephrol Dial Transplant 19:1964-8. 2004

Collaborators

Detail Information

Publications9

  1. ncbi Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation
    A D Booth
    Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Circulation 109:1718-23. 2004
    ....
  2. ncbi Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
    Anthony D Booth
    Department of Medicine, Addenbrookes s Hospital, Cambs, UK
    Am J Kidney Dis 41:776-84. 2003
    ..Renal involvement is frequently present in antineutrophil cytoplasmic autoantibody (ANCA)-associated systemic vasculitis and is an important cause of end-stage renal failure (ESRF)...
  3. ncbi Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis
    Anthony Booth
    Department of Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Am Soc Nephrol 15:717-21. 2004
    ..Tumor necrosis factor alpha (TNFalpha) plays an important role in the pathogenesis of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. TNFalpha blockade is a potential therapy for these disorders...
  4. ncbi Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom
    J Am Coll Cardiol 50:852-8. 2007
    ..The aim of this study was to investigate the effect of simvastatin and ezetimibe on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in a cohort of rheumatoid arthritis (RA) patients...
  5. ncbi Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction
    Sharon M L Wallace
    Clinical Pharmacology, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Hypertension 50:228-33. 2007
    ..Our results suggest that endothelial function contributes significantly to increased arterial stiffness in patients with isolated systolic hypertension and with age...
  6. ncbi Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge, UK
    Int J Cardiol 129:399-405. 2008
    ..The aim of the study was to establish the contribution of iNOS to endothelial function...
  7. ncbi Immunotherapy for autoimmune and inflammatory renal diseases
    Anthony D Booth
    Department of Renal Medicine (Box 118, Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 2QQ, UK
    Expert Opin Biol Ther 3:487-500. 2003
    ..Larger, randomised comparisons to standard therapy are needed along with assessment of long-term efficacy and safety...
  8. ncbi Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge CB2 2QQ, United Kingdom
    Circulation 114:1185-92. 2006
    ..In addition, we tested the hypothesis that aortic stiffness could be reduced with anti-tumor necrosis factor-alpha (TNF-alpha) therapy...
  9. ncbi Renal vasculitis--an update in 2004
    Anthony D Booth
    Nephrol Dial Transplant 19:1964-8. 2004